Patients with Multiple Myeloma (MM) are at increased risk of venous thromboembolic event, especially in newly diagnosed patients and during induction treatment with thalidomide in combination with dexamethasone. This association was mainly heightened during the 3 first months of chemotherapy. Several coagulation abnormalities have been described. Laboratory tests measuring the overall thrombophilic tendency might be useful to assess thrombosis risk. The aim of this study is to compare thrombin generation by calibrated automated thrombogram during the 3 first cycles of chemotherapy in patients with newly diagnosed MM.
Study Type
OBSERVATIONAL
Enrollment
71
CHU de Clermont Ferrand
Clermont-Ferrand, France
CHU de Nancy
Nancy, France
Service de Médecine Interne - CHU de Saint Etienne
Saint-Etienne, France
Service de rhumatologie - CHU de Saint Etienne
Saint-Etienne, France
Service d'hématologie - ICL
Saint-Priest-en-Jarez, France
change from baseline in Thrombin generation measure
change from baseline in Thrombin generation measure
Time frame: day 21
change from baseline in Thrombin generation measure
change from baseline in Thrombin generation measure
Time frame: day 42
change from baseline in Thrombin generation measure
change from baseline in Thrombin generation measure
Time frame: day 63
change from baseline in Thrombin generation measure
change from baseline in Thrombin generation measure
Time frame: day 0
image-confirmed venous thromboembolic events
Estimate the incidence of venous thromboembolic events until day 63
Time frame: day 63
change from baseline in TFPI resistance measure
change from baseline in TFPI resistance measure
Time frame: day 21
change from baseline in acquired protein S deficiency measure
change from baseline in acquired protein S deficiency measure
Time frame: day 21
change from baseline in TFPI resistance measure
change from baseline in TFPI resistance measure
Time frame: day 42
change from baseline in TFPI resistance measure
change from baseline in TFPI resistance measure
Time frame: day 63
change from baseline in acquired protein S deficiency measure
change from baseline in acquired protein S deficiency measure
Time frame: day 42
change from baseline in acquired protein S deficiency measure
change from baseline in acquired protein S deficiency measure
Time frame: day 63
change from baseline in TFPI resistance measure
change from baseline in TFPI resistance measure
Time frame: day 0
change from baseline in acquired protein S deficiency measure
change from baseline in acquired protein S deficiency measure
Time frame: day 0
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.